Novartis Japan Chief Sees CAR-T Pricing as “Important Issue” Here Too

Novartis Pharma President Kazunari Tsunaba Novartis AG’s Japan helmsman Kazunari Tsunaba is bracing for a challenge he will face on the pricing of the company’s chimeric antigen receptor T cell (CAR-T) therapy in his country, as its US$475,000 price tag...read more